Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.79
KMDA's Cash to Debt is ranked higher than
64% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. KMDA: 3.79 )
KMDA' s 10-Year Cash to Debt Range
Min: 1.32   Max: No Debt
Current: 3.79

Equity to Asset 0.62
KMDA's Equity to Asset is ranked higher than
70% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KMDA: 0.62 )
KMDA' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.65
Current: 0.62

0.28
0.65
Interest Coverage 1.17
KMDA's Interest Coverage is ranked lower than
53% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KMDA: 1.17 )
KMDA' s 10-Year Interest Coverage Range
Min: 1.17   Max: 1.26
Current: 1.17

1.17
1.26
F-Score: 3
Z-Score: 1.52
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -15.16
KMDA's Operating margin (%) is ranked higher than
80% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. KMDA: -15.16 )
KMDA' s 10-Year Operating margin (%) Range
Min: -121.42   Max: 5.83
Current: -15.16

-121.42
5.83
Net-margin (%) -18.18
KMDA's Net-margin (%) is ranked higher than
79% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. KMDA: -18.18 )
KMDA' s 10-Year Net-margin (%) Range
Min: -170.4   Max: 0.63
Current: -18.18

-170.4
0.63
ROE (%) -15.32
KMDA's ROE (%) is ranked higher than
80% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. KMDA: -15.32 )
KMDA' s 10-Year ROE (%) Range
Min: -196.96   Max: 1.83
Current: -15.32

-196.96
1.83
ROA (%) -9.52
KMDA's ROA (%) is ranked higher than
81% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. KMDA: -9.52 )
KMDA' s 10-Year ROA (%) Range
Min: -59.2   Max: 0.58
Current: -9.52

-59.2
0.58
ROC (Joel Greenblatt) (%) -26.31
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. KMDA: -26.31 )
KMDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -179.63   Max: 27.3
Current: -26.31

-179.63
27.3
Revenue Growth (3Y)(%) 43.70
KMDA's Revenue Growth (3Y)(%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. KMDA: 43.70 )
KMDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 19.2   Max: 43.7
Current: 43.7

19.2
43.7
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

KMDA Guru Trades in Q4 2013

Jim Simons 10,543 sh (New)
John Paulson 750,000 sh (unchged)
Steven Cohen Sold Out
» More
Q1 2014

KMDA Guru Trades in Q1 2014

Jim Simons 22,600 sh (+114.36%)
John Paulson 750,000 sh (unchged)
» More
Q2 2014

KMDA Guru Trades in Q2 2014

Jim Simons 70,265 sh (+210.91%)
John Paulson 750,000 sh (unchged)
» More
Q3 2014

KMDA Guru Trades in Q3 2014

John Paulson 750,000 sh (unchged)
Jim Simons 67,740 sh (-3.59%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2013-06-30 New Buy0.06%$9.82 - $11.16 $ 3.55-66%750000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
KMDA's P/B is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. KMDA: 1.60 )
KMDA' s 10-Year P/B Range
Min: 1.44   Max: 11.59
Current: 1.6

1.44
11.59
P/S 1.78
KMDA's P/S is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. KMDA: 1.78 )
KMDA' s 10-Year P/S Range
Min: 1.61   Max: 13.49
Current: 1.78

1.61
13.49
EV-to-EBIT -7.58
KMDA's EV-to-EBIT is ranked higher than
60% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. KMDA: -7.58 )
KMDA' s 10-Year EV-to-EBIT Range
Min: -177.7   Max: 606.1
Current: -7.58

-177.7
606.1
Current Ratio 3.32
KMDA's Current Ratio is ranked higher than
67% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. KMDA: 3.32 )
KMDA' s 10-Year Current Ratio Range
Min: 2.21   Max: 4.42
Current: 3.32

2.21
4.42
Quick Ratio 2.50
KMDA's Quick Ratio is ranked higher than
64% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. KMDA: 2.50 )
KMDA' s 10-Year Quick Ratio Range
Min: 1.45   Max: 3.59
Current: 2.5

1.45
3.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.92
KMDA's Price/Net Cash is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. KMDA: 9.92 )
KMDA' s 10-Year Price/Net Cash Range
Min: 12.07   Max: 26.48
Current: 9.92

12.07
26.48
Price/Net Current Asset Value 3.20
KMDA's Price/Net Current Asset Value is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. KMDA: 3.20 )
KMDA' s 10-Year Price/Net Current Asset Value Range
Min: 3.89   Max: 10.9
Current: 3.2

3.89
10.9
Price/Tangible Book 1.59
KMDA's Price/Tangible Book is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. KMDA: 1.59 )
KMDA' s 10-Year Price/Tangible Book Range
Min: 1.94   Max: 10.24
Current: 1.59

1.94
10.24
Price/Median PS Value 0.37
KMDA's Price/Median PS Value is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. KMDA: 0.37 )
KMDA' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 2.81
Current: 0.37

0.45
2.81
Earnings Yield (Greenblatt) -13.20
KMDA's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. KMDA: -13.20 )
KMDA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 2.5
Current: -13.2

0.2
2.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KMDA.Israel,
Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its human Alpha-1... Dec 14 2014
OMBP: Omni Bio's Hand Gets Stronger As AAT Shows Potential In GvHD Dec 11 2014
Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1... Dec 11 2014
Kamada Announces Third Quarter 2014 Financial Results Nov 12 2014
Kamada Announces Third Quarter 2014 Financial Results Nov 12 2014
Kamada to Host Third Quarter 2014 Financial Results Conference Call on November 12, 2014 Nov 10 2014
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease Oct 30 2014
FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease Oct 29 2014
Kamada Announces Study in Support of Alpha-1 Antitrypsin for the Treatment of Type-1 Diabetes... Oct 21 2014
Kamada extends emphysema drug deal with Baxter through 2017 Sep 29 2014
Kamada Announces Second Extension of Strategic Agreement with Baxter Sep 29 2014
Silver Spring Networks Starts The Week Strong Sep 08 2014
Midday Losers From Thursday, September 4 Sep 04 2014
Kamada Plunges Following Missed Marks In Trial Sep 04 2014
Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat... Sep 04 2014
Kamada to Announce Final Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1... Sep 03 2014
Kamada Reports Second Quarter Financial Results Aug 14 2014
Kamada to Host Second Quarter Financial Results Conference Call on Thursday, August 14, 2014 Aug 06 2014
Should You Get Rid of Kamada (KMDA) Now? Jul 11 2014
Should You Get Rid of Kamada (KMDA) Now? May 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK